Breztri is a new inhaler that will be approved for COPD. Breztri is a combination of 3 medications, budesonide/glycopyrronium/formoterol fumarate. Each of these medications have been used to treat COPD (chronic obstructive pulmonary disease), and used in combination, it has been shown to decrease the rate of moderate or severe exacerbations.
We have spoken about another triple therapies in the past:
Breztri Aerosphere consists of 3 medications:
- Budesonide-a steroid inhaler
- glycopyrronium-muscarinic anticholinergic group
- Formoterol fumarate-a Long acting beta-2-agonist
Studies have shown that Breztri Aerosphere was well tolerated, the most frequent adverse events were nasopharyngitis, COPD and upper respiratory tract infection.
“The Phase III ETHOS trial results are exciting and demonstrate that Breztri Aerosphere significantly reduces the rate of exacerbations,” stated Klaus Rabe, professor of Pulmonary Medicine at the University of Kiel, director of the Department of Pneumology at Clinic Grosshansdorf, Germany, and lead investigator of the ETHOS trial. “This is also the first time we have seen the benefit of fixed-dose triple-combination therapy at two inhaled corticosteroid doses, which could transform treatment practice by allowing physicians to select the optimal dose for individual patients.”
ETHOS is part of AstraZeneca’s ATHENA clinical trial program for Breztri Aerosphere, which has more than 15,500 patients around the world in 11 clinical trials. The four primary trials are ETHOS, KRONOS, TELOS and SOPHOS.
A major question for these triple therapy medications is whether or not they will be approved for asthma. Current asthma medications like Advair, Symbicort, Dulera, Breo and AirDuo contain both inhaled steroids and a long acting beta agonist. The 3rd ingredient the anticholenergic in these medications have not been given FDA approval yet in these fixed products. Allergists do currently use them in some difficult to control asthmatic patients, Spiriva is one that is commonly used currently.
Breztri Aerosphere should be out soon, AstraZeneca currently has a website set up for its latest news.